Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population
Top Cited Papers
- 27 March 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 27 (6), 973-979
- https://doi.org/10.1097/qad.0b013e32835cae9c
Abstract
Due to the success of antiretroviral therapy (ART), it is relevant to ask whether death rates in optimally treated HIV are higher than the general population. The objective was to compare mortality rates in well controlled HIV-infected adults in the SMART and ESPRIT clinical trials with the general population. Non-IDUs aged 20-70 years from the continuous ART control arms of ESPRIT and SMART were included if the person had both low HIV plasma viral loads (≤400 copies/ml SMART, ≤500 copies/ml ESPRIT) and high CD4(+) T-cell counts (≥350 cells/μl) at any time in the past 6 months. Standardized mortality ratios (SMRs) were calculated by comparing death rates with the Human Mortality Database. Three thousand, two hundred and eighty individuals [665 (20%) women], median age 43 years, contributed 12,357 person-years of follow-up. Sixty-two deaths occurred during follow up. Commonest cause of death was cardiovascular disease (CVD) or sudden death (19, 31%), followed by non-AIDS malignancy (12, 19%). Only two deaths (3%) were AIDS-related. Mortality rate was increased compared with the general population with a CD4(+) cell count between 350 and 499 cells/μl [SMR 1.77, 95% confidence interval (CI) 1.17-2.55]. No evidence for increased mortality was seen with CD4(+) cell counts greater than 500 cells/μl (SMR 1.00, 95% CI 0.69-1.40). In HIV-infected individuals on ART, with a recent undetectable viral load, who maintained or had recovery of CD4(+) cell counts to at least 500 cells/μl, we identified no evidence for a raised risk of death compared with the general population.Keywords
This publication has 19 references indexed in Scilit:
- Projected life expectancy of people with HIV according to timing of diagnosisAIDS, 2012
- Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individualsAIDS, 2010
- Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV InfectionThe Journal of Infectious Diseases, 2010
- Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countriesInternational Journal of Epidemiology, 2009
- Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated MortalityPLoS Medicine, 2009
- The role of HIV in serious diseases other than AIDSAIDS, 2008
- Viral Hepatitis in HIV InfectionNew England Journal of Medicine, 2007
- CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic SuppressionClinical Infectious Diseases, 2007
- Inflamm‐ageing and lifelong antigenic load as major determinants of ageing rate and longevityFEBS Letters, 2005
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003